Annovis Bio (NYSE: ANVS) has entered a collaboration with Weave Bio to support preparation of the planned New Drug Application (NDA) for buntanetap, its investigational oral therapy for neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). The company will use the Weave AI platform to draft, review, and manage NDA documents, while its regulatory and clinical teams will retain responsibility for content, verification, and final approval of all documents submitted to the U.S. Food and Drug Administration (FDA). The full press release is available at https://ibn.fm/FMiEX.
The collaboration follows the completion of enrollment in Annovis's pivotal Phase 3 AD study, which enrolled 862 biomarker-confirmed patients, exceeding the original target of 760. Annovis aims to achieve database lock for the six-month treatment period in December 2026, followed by top-line symptomatic data in March 2027, with the company seeking to have most of the NDA prepared before the data readout. Using AI to prepare the NDA ahead of data readout could significantly shorten the timeline from data to submission, a critical advantage in the competitive neurodegenerative space.
Buntanetap is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The potential to treat both AD and PD with a single oral agent sets buntanetap apart from many approaches that target only one protein or disease.
Annovis Bio, headquartered in Malvern, Pennsylvania, is a Phase 3 clinical-stage biotechnology company. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X. The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS.
This collaboration matters because it signals a broader trend in biotech: leveraging artificial intelligence to navigate the complex regulatory landscape. By preparing most of the NDA before the Phase 3 readout, Annovis could reduce the time between data availability and submission, potentially bringing buntanetap to patients faster. If successful, this approach could serve as a model for other companies seeking to expedite their own filings. The news was distributed by BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which offers wire solutions through InvestorWire, editorial syndication to over 5,000 outlets, press release enhancement, and social media distribution. For more information, visit https://www.BioMedWire.com.
